Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFQ056 in SSRI-resistant OCD
NCT01813019Phase 2Terminated
- Sponsor
- Novartis
- Start
- Nov 2013
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in obsessive compulsive disorder (OCD) comparing AFQ056 with Placebo (2 arms). Primary endpoint: Yale-Brown Obsessive Compulsive Scale at 17 weeks. Started Nov 2013; status: terminated.
02
Drugs
mavoglurant
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on NCT01813019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01813019.